Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
Stanley Cohan1,2,3 1Providence Multiple Sclerosis Center, 2Providence Brain and Spine Institute, 3Providence Health & Services, Portland, OR, USA Abstract: Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly efficacious targeted therapy with a laguna 3hp dust co